Radiation Union Technology has secured $77 million in financing to advance its global radioactive drug pipeline and construct a production facility in Belgium.
Target Company Overview
Radiation Union Technology, a comprehensive and integrated clinical-stage international company specializing in radioactive drug therapy, has recently completed a financing round amounting to $77 million. This includes approximately $50 million in Series C equity financing and an additional $27 million in debt financing. The funds raised will be directed toward advancing the company’s global pipeline of radioactive drugs as well as the construction of its production facility in Belgium.
Since its establishment in 2021, Radiation Union Technology has successfully garnered nearly $200 million in cumulative financing that includes equity deals, debt financing, and business development transactions. The company operates offices in Belgium, Germany, and China, focusing on creating a comprehensive nuclear medicine enterprise that integrates R&D, production, and commercialization of radioactive drugs.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Belgium
Belgium's biotechnology and pharmaceutical industry is characterized by robust growth, supported by a strong research infrastructure and favorable regulatory environments. The country is known f
Similar Deals
Adicon Holdings Limited → Crown Bioscience Inc.
2026
佳辰资本
invested in
辐联科技
in 2025
in a Other deal
Disclosed details
Transaction Size: $77M
Equity Value: $50M